Topic: marketing approval
Tally another win for Bristol-Myers Squibb’s immunotherapy combination, this time in rare colon cancers.
The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.
It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.
Phase 1 of Bayer’s liver cancer plan is complete: Build a bridge between Stivarga and first-line blockbuster Nexavar.
The new multiple sclerosis med Roche has been anticipating—and the market shake-up other drugmakers have been dreading—is here.
Amgen was aiming to launch its cholesterol-fighter Repatha quickly in India. But a panel of CV and renal specialists blocked the PCSK9 drug instead.
Samsung Bioepis received acceptance of a European Marketing Authorization application for a biosimilar of AbbVie's blockbuster Humira.
China pilot for drug marketing authorization aimed at innovative firms.